Orthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says

MT Newswires Live

04/21

Orthocell's (ASX:OCC) fiscal year 2026 revenue is now estimated to reach AU$13.4 million, revised down from AU$14.4 million, Euroz Hartleys said in a note on Tuesday.

Orthocell said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir. Its management attributed the flat quarterly revenue growth to seasonality.

Euroz Hartleys says that Orthocell has delivered around 8.5% compound quarterly revenue growth over the past 15 quarters.

The investment firm maintained its speculative buy recommendation on Orthocell and lowered its price target to AU$1.09 per share from AU$1.19 per share.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2629771701"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629771701\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629771701?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 12:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629771701","market":"hk","top_or_hot":-1,"title":"Orthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says","media":"MT Newswires Live","content":"<html><body><p> Orthocell's (ASX:OCC) fiscal year 2026 revenue is now estimated to reach AU$13.4 million, revised down from AU$14.4 million, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a note on Tuesday.</p><p>Orthocell said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir. Its management attributed the flat quarterly revenue growth to seasonality.</p><p>Euroz Hartleys says that Orthocell has delivered around 8.5% compound quarterly revenue growth over the past 15 quarters.</p><p>The investment firm maintained its speculative buy recommendation on Orthocell and lowered its price target to AU$1.09 per share from AU$1.19 per share.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-21 12:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Orthocell's (ASX:OCC) fiscal year 2026 revenue is now estimated to reach AU$13.4 million, revised down from AU$14.4 million, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a note on Tuesday.</p><p>Orthocell said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir. Its management attributed the flat quarterly revenue growth to seasonality.</p><p>Euroz Hartleys says that Orthocell has delivered around 8.5% compound quarterly revenue growth over the past 15 quarters.</p><p>The investment firm maintained its speculative buy recommendation on Orthocell and lowered its price target to AU$1.09 per share from AU$1.19 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2629771701","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629771701","pubTimestamp":1776746594,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Orthocell's  fiscal year 2026 revenue is now estimated to reach AU$13.4 million, revised down from AU$14.4 million, Euroz Hartleys said in a note on Tuesday.Orthocell said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir. Its management attributed the flat quarterly revenue growth to seasonality.Euroz Hartleys says that Orthocell has delivered around 8.5% compound quarterly revenue growth over the past 15 quarters.The investment firm maintained its speculative buy recommendation on Orthocell and lowered its price target to AU$1.09 per share from AU$1.19 per share.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","OCC.AU":"ORTHOCELL LTD"},"translate_title":"Euroz Hartleys表示，Orthocell 2026财年收入预期下调至1,340万澳元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC.AU":1},"content_text":"Orthocell's (ASX:OCC) fiscal year 2026 revenue is now estimated to reach AU$13.4 million, revised down from AU$14.4 million, Euroz Hartleys said in a note on Tuesday.Orthocell said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir. Its management attributed the flat quarterly revenue growth to seasonality.Euroz Hartleys says that Orthocell has delivered around 8.5% compound quarterly revenue growth over the past 15 quarters.The investment firm maintained its speculative buy recommendation on Orthocell and lowered its price target to AU$1.09 per share from AU$1.19 per share.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}